Abemaciclib Displays Manageable and Reversible Safety Profile in monarchE PRO Findings for HR+/HER2– Breast Cancer
When administered with endocrine therapy, adjuvant abemaciclib (Verzenio) demonstrated a tolerable as well as reversable safety profile, according to long-term, patient-reported outcome data from the monarchE study (NCT0315597) in patients with hormone receptor–positive, HER2-negative, node-positive, high-risk, early breast cancer.1 In a presentation of the safety data at the 2023 European Society for Medical Oncology Breast … [Read more…]